# Derivatives of benzo(5,6)cyclohepta(1,2-b)pyridine, pharmaceutical composition and methods of inhibiting abnormal cell growth and farnesyl-protein transferase

The invention relates to new compounds derived from benzo(5,6)-cyclohepta-(1,2)-pyridine of the formula I, where R

^{1}means of groups a), b), C), d), e), f), i) k) l) m) n) o) p), r), s); R

^{2}and R

^{3}together form a bond when the value of R

^{1}- group a) or group m) or mean hydrogen for the other R

^{1}; R

^{4}the hydrogen for the other R

^{1}or bromine when the value of R

^{1}group o) or group f); R

^{5}the hydrogen for the other R

^{1}or bromine for R

^{1}group r or group s), and their pharmaceutically acceptable salts or solvate. This invention also relates to a method for inhibiting the abnormal growth of cells, comprising introducing an effective amount of compounds of formula I, the method of inhibiting farnesyl-protein transferase responsible for pancreatic cancer, lung cancer, myeloid leukemia, follicular thyroid cancer, myelodysplasia syndrome, epidermal carcinoma, carcinoma of the bladder, colon cancer, breast cancer or prostate cancer in a patient, ordaudio such inhibition, comprising introducing an effective amount of the compounds of formula I. the Invention also relates to a pharmaceutical composition having activity pharmaceutically acceptable carrier. 4 C. and 6 C.p. f-crystals, 1 PL.

Description text in facsimile form (see graphic part).

Claims

^{1}means a group ofR

^{2}and R

^{3}together form a bond;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}who appoints the groupR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}together form a bond;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means € bromine;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means bromine;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine;and their pharmaceutically acceptable salts or solvate.2. Derivatives of benzo(5,6)cyclohepta(1,2-b)pyridine formula I on p. 1, where R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group of

>^{5}means hydrogen;

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}together form a bond;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means bromine;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means bromine;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine.3. Derivatives of benzo(5,6)cyclohepta(1,2-b)pyridine formula I on p. 1, whereR

^{1}means a group ofR

^{2}and R

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means hydrogen;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine;or R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine.4. Derived benzo(5,6)cyclohepta(1,2-b)pyridine formula I on p. 1, where R

^{1}means a group ofR

^{2}and R

^{3}mean hydrogen;R

^{4}means hydrogen;R

^{5}means bromine.5. Method of inhibiting abnormal cell growth, including the introduction of an effective amount of the compounds under item 1.6. The method according to p. 5, in which inhibiting the cells are tumor cells expressing an activated ras oncogene.7. The method according to p. 5, in which the inhibition of abnormal cell growth inhibition is farnesyl-protein transferase.8. The method according to p. 5, which inhibit tumor cells in which the Ras protein is activated in uncage the military for pancreatic cancer, lung cancer, myeloid leukemia, follicular thyroid cancer, myelodysplasia syndrome, epidermal carcinoma, carcinoma of the bladder, colon cancer, breast cancer or prostate cancer in a patient in need of such inhibition, comprising introducing an effective amount of the compounds under item 1 or 3.10. Pharmaceutical composition having activity of inhibiting abnormal cell growth comprising an effective amount of the compounds under item 1 or 3 in combination with a pharmaceutically acceptable carrier.

**Same patents:**

The invention relates to new derivatives of 2-aminopyridine F.-ly (1) where denotes unsubstituted or substituted phenyl, pyridyl, thienyl, thiazolyl, hinely, cinoxacin-2-yl or Antonelliana derivatives; D is unsubstituted or substituted phenyl, pyridyl, thienyl, pyrimidyl, indolyl, thiazolyl, imidazolyl, hinely, triazolyl, oxazolyl, isoxazolyl or Antonelliana derivatives, provided that C and D are not simultaneously have the following values: S - phenyl, and D is phenyl, S - phenyl, and D - pyridyl, With - pyridyl and D - phenyl, - pyridyl and D - pyridyl; R

^{1}- R^{4}- hydrogen, NO_{2}or NH_{2}The invention relates to amide derivative of the formula I

< / BR>

in which R

< / BR>

in which R

^{3}stands WITH_{1}-C_{6}alkyl or halogen; Q^{1}denotes heteroaryl, which is optionally substituted by 1, 2, 3 or 4 substituents selected from the group comprising hydroxy, halogen, trifluoromethyl, cyano, amino, C_{1}-C_{6}alkyl, C_{2}-C_{6}alkenyl,_{2}-C_{6}quinil,_{1}-C_{6}alkoxy, etc., R^{2}denotes hydroxy, halogen, C_{1}-C_{6}alkyl, C_{2}-C_{6}alkenyl,_{2}-C_{6}quinil,_{1}-C_{6}alkoxy, p = 0, 1, or 2; q = 0, 1, 2, 3 or 4; and Q^{2}denotes aryl, aryl-C_{1}-C_{6}alkoxy, aryloxy, arylamino, N-C_{1}-C_{6}alkylamino, aryl-C_{1}-C_{6}alkylamino, cycloalkyl, heteroaryl, heteroallyl, heteroaryl-C_{1}-C_{6}alkylamino or heterocyclyl and so on, or its pharmaceutically acceptable salt or cleaved in vivo ester2-substituted 4,5-diariomotor, method of preparation and pharmaceutical composition based on them // 2214408

The invention relates to 2-substituted 4,5-dailyedition General formula (I), where R

_{1}- 4-pyridyl; R_{2}- phenyl, naphthas-1-yl or naphthas-2-yl, which optionally can contain up to 5 substituents selected from halogen; R_{3}is hydrogen; R_{4}- pyridyl, optionally substituted with halogen or amino groupHintline inhibiting farnesyltransferase // 2205831

The invention relates to a new 1.8-fused derivative of 2-Hinayana formula (I), where A, X, R

^{1}, R^{2}, R^{3}, R^{4}, R^{5}, R^{6}such as defined in the claimsNew pyrimidine derivatives (options) // 2203894

The invention relates to new pyrimidine derivative of General formula (I) or their pharmaceutically acceptable salts, with high antisecretory activity with the properties of reversible proton pump inhibitor that can be used to obtain valuable medicines

The invention relates to 4-geterotsiklicheskikh-6-methoxy-5-(2-methoxyphenoxy)-2-pyridinedimethanol derivative of the formula I, in which R

^{1}denotes a heterocyclic fragment selected from pyridyl and thiazolyl, where the heterocyclic fragment optionally may be substituted (NISSThe invention relates to new derivatives of 2-aminopyridine F.-ly (1) where denotes unsubstituted or substituted phenyl, pyridyl, thienyl, thiazolyl, hinely, cinoxacin-2-yl or Antonelliana derivatives; D is unsubstituted or substituted phenyl, pyridyl, thienyl, pyrimidyl, indolyl, thiazolyl, imidazolyl, hinely, triazolyl, oxazolyl, isoxazolyl or Antonelliana derivatives, provided that C and D are not simultaneously have the following values: S - phenyl, and D is phenyl, S - phenyl, and D - pyridyl, With - pyridyl and D - phenyl, - pyridyl and D - pyridyl; R

^{1}- R^{4}- hydrogen, NO_{2}or NH_{2}Derivative amide, the method of production thereof and pharmaceutical composition based on them // 2219171

The invention relates to amide derivative of the formula I

< / BR>

where R

< / BR>

where R

^{3}represents (1-6C)alkyl or halogen; m is 0, 1, 2 or 3; R^{1}represents hydroxy, halogen, trifluoromethyl, nitro, amino, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)quinil, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl] amino, amino-(2-6C)alkylamino, (1-6C)alkylamino-(2-6C)alkylamino etcHydroxyindoles, their use as inhibitors of phosphodiesterase 4 and the method of production thereof // 2217422

The invention relates to new hydroxyindole General formula

< / BR>

where R

< / BR>

where R

^{1}- C_{1}-C_{12}-alkyl, linear or branched, if necessary monosubstituted monocyclic saturated or polyunsaturated carbocycles with 6 ring members, WITH_{6}-aryl group and closed carbocyclic substituents on its part, if necessary, can be mono - or polyamidine R^{4}; R^{5}- monocyclic polyunsaturated carbocycles with 6 ring members, mono - or politeley atoms, halogen or a monocyclic polyunsaturated heterocycles with 6 ring members, one of which is N as heteroatom, mono - or politeley atoms of halogen; R^{2}and R^{3}can be hydrogen or HE, and at least one or both of the Deputy should be-HE; R^{4}means-H, -OH, -F, -Cl, -J, -Br, -O-C_{1}-C_{6}-alkyl, -NO_{2}; A -, or a bond, or -(CHOZ)_{m}-(C= 0)-, and m= 0The invention relates to derivatives of cyclic amines and their use as pharmaceuticals, particularly to a compound represented by the General formula (I), its pharmaceutically acceptable acid additive salts or its pharmaceutically acceptable C

_{1}-C_{6}alcaldicios salt, R^{1}-phenyl, C_{3-8}-cycloalkyl, aromatic heterocycle with 1-3 heteroatoms selected from O, S, N, or combinations thereof, and these groups may be condensed with benzene ring or an aromatic heterocyclic group with heteroatoms, selected from O, S or N, or combinations thereof, and may also have different substituentsThe invention relates to a group of new compounds - heterocyclic derivatives of glycyl-beta-alanine General formula I

< / BR>

or pharmaceutically acceptable salt of this compound, where

< / BR>

is a 5-8-membered monocyclic heterocyclic, optionally unsaturated ring containing from 1 to 4 heteroatoms selected from the group comprising N and S, and

< / BR>

is not pyrrolidinium when V represents NH;

A represents a group of the formula

< / BR>

where Y

where R

< / BR>

where R

< / BR>

or pharmaceutically acceptable salt of this compound, where

< / BR>

is a 5-8-membered monocyclic heterocyclic, optionally unsaturated ring containing from 1 to 4 heteroatoms selected from the group comprising N and S, and

^{1}selected from the group comprising SN, SN_{2}, N, NH, O and S, provided that< / BR>

is not pyrrolidinium when V represents NH;

A represents a group of the formula

< / BR>

where Y

^{1}selected from the group comprising N-R^{2}and R^{2}means hydrogen; R^{2}means hydrogen, R^{7}when not with R^{2}and R^{8}mean hydrogen, alkyl, substituted alkoxy group, or R^{2}together with R^{7}form a 4 to 12-membered ring containing 2 nitrogen atom a heterocycle, optionally substituted by one or more substituents selected from the group comprising hydroxy, C_{1}-C_{10}< / BR>where R

^{2}together with R^{7}form a 5-8-membered ring containing two nitrogen atom a heterocycle, R^{5}means hydrogen, R^{8}means alkyl, optionally substituted by alkoxygroup; or A signifies a group< / BR>

where R

^{2}together with R^{7}form a 5-8-membered ring containing 2 nitrogen atom a heterocycle, optionally substituted hydroxy-group; R^{8}- alkyl, substituted alkoxygroup; V means-N(R^{6})-; R^{6}is hydrogen; Y and Z denote hydrogen, t = 0, n and R = 1, 2; R means X-R^{3}where X is-O-; R^{3}is hydrogen, alkyl; R^{1}selected from the group including aryl, alkyl, optionally substituted one or more times by halogen, alkyl, HE; monocyclic heterocycle; haloalkyl; R^{11}means hydrogen, or a pharmaceutically acceptable salt of the compounds; pharmaceutical compositions having properties antagonist_{V}_{3}-integrin, as well as to a method of treating diseases mediated_{V}_{3}-integrin in a mammalThe invention relates to derivatives of 2-(arylvinyl)aminoimidazole formula I, where R

^{1}denotes a group of formula (A), (B) or (C), a R^{2}, R^{3}, R^{4}, R^{5}, R^{6}and X are such as defined in the claimsThe way to get omeprazole // 2211218

The invention relates to a new process for the preparation of omeprazole, which is effective as an inhibitor of the secretion of gastric acid and is useful as an antiulcer agent

The invention relates to new derivatives of amides and urea of the formula I

R

in which R

< / BR>

< / BR>

or

< / BR>

m = 1 or 2; n = 0, 1, 2, 3 or 4; Y is 2,4-cyclohexylamine, 1,3 - pyrrolidinone, 1,4-piperazinone or 1,4-piperidinylidene ring, which may also be partially digidrirovanny; Z - (CH

R

^{1}-(CH_{2})_{n}(Y)_{q}-(Z)_{r}-CO-NH-R^{2}(I)in which R

^{1}- 3-indolyl, unsubstituted or monosubstituted, AO, Hal, CN;^{2}represents a< / BR>

< / BR>

or

< / BR>

m = 1 or 2; n = 0, 1, 2, 3 or 4; Y is 2,4-cyclohexylamine, 1,3 - pyrrolidinone, 1,4-piperazinone or 1,4-piperidinylidene ring, which may also be partially digidrirovanny; Z - (CH

_{2})_{n}NH-, q = 0 or 1; r = 0 or 1; R^{3}- A; R^{4}- AO; Hal Is F, Cl, Br, J; A - unbranched or branched C_{1}-C_{6}alkyl, provided that q and r are not simultaneously equal to 0, and their physiologically acceptable saltsAmides of acids, method for their production and pharmaceutical composition based on them // 2208608

The invention relates to new Amida acids of the formula I

< / BR>

where R

< / BR>

where R

^{1}- C_{1}-C_{6}alkanoyl,_{1}-C_{6}alkoxycarbonyl, benzoyl, benzoyl substituted halogen (C_{1}-C_{6})-alkoxy, C_{1}-C_{6}alkylsulfonyl, phenylsulfonyl, phenylsulfonyl, substituted with halogen, or cyclo (C_{3}-C_{6}) alkylsulphonyl, R^{2}- phenyl, phenyloxy or phenylamino, where each phenyl may be substituted with halogen; pyridyl or pyridylamino, a represents a single bond, E is ethylene, X represents CH, Y is-NR^{5}where R^{5}is hydrogen, Q is-C(O)- or-SO_{2}-, R^{3}and R^{4}together form ethylene, or their pharmaceutically acceptable salts